Characteristics of Buserelin-depo use in the treatment for comorbid pathologies of reproductive organs

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Proliferative diseases present an important issue in contemporary gynecology. Among gynecological diseases, combinations of benign proliferative diseases represent up to 85% of cases. This pathology is most frequently detected in patients aged 40-45 years. Comorbid proliferative diseases are among the most common indications for radical hysterectomy, a procedure that is complicated by the development of post-hysterectomy syndrome. This condition significantly reduces the quality of life and performance of relatively young women.

The gold standard of therapy for comorbid proliferative disorders is the use of gonadotropin-releasing hormone agonists, which block sex hormone synthesis and have marked antiproliferative, antiangiogenic and anti-inflammatory effects.

This article presents a review of the scientific literature data on the use of the drug Buserelin-depo in the treatment of comorbid proliferative diseases.

Conclusion: According to the literature, the use of Buserelin-depo in the complex therapy for comorbid diseases can lead to a reduction in the size of the enlarged uterus, relatively rapid relief of pain syndrome and abnormal uterine bleeding, reduction in the risk of postoperative complications and recurrences. This significantly improves the quality of life of this group of patients, reduces the number of radical treatments and improves the outcomes of organ-preserving surgeries.

Full Text

Restricted Access

About the authors

Asiyat Z. Khashukoeva

Pirogov Russian National Research Medical

Author for correspondence.
Email: azk@mail.ru
ORCID iD: 0000-0001-7591-6281

Dr. Med. Sci., Professor, Professor at the Department of Obstetrics and Gynecology, Faculty of Medicine

Russian Federation, University, Ministry of Health of Russia 117997, Moscow, Ostrovityanov str., 1

Madina I. Agaeva

Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: madlen1690@mail.ru
ORCID iD: 0000-0001-5138-8357

PhD, Teaching Assistant at the Department of Obstetrics and Gynecology, Faculty of Medicine

Russian Federation, 117997, Moscow, Ostrovityanov str., 1

Zoya A. Agaeva

Sklifosovsky Research Institute for Emergency Мedicine

Email: zoya466@mail.ru
ORCID iD: 0000-0002-2205-0880

Dr. Med. Sci., Professor, Senior Lecturer at the Department of Ultrasound and Functional Research Methods

Russian Federation, 129090, Moscow, B. Sukharevskaya sqr., 3

Yulia I. Lobacheva

Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: mitu.10@mail.ru
ORCID iD: 0009-0007-9652-3568

Teaching Assistant at the Department of Obstetrics and Gynecology, Faculty of Medicine

Russian Federation, 117997, Moscow, Ostrovityanov str., 1

Yulia A. Smagina

Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: yulia-smagina709@mail.ru
ORCID iD: 0009-0009-3893-4988

student

Russian Federation, 117997, Moscow, Ostrovityanov str., 1

References

  1. Савельева Г.М., Сухих Г.Т., Серов В.Н, Радзинский В.Е., Манухин И.Б., ред. Национальное руководство. Гинекология. М.: ГЭОТАР-Медиа; 2022. 1008 с. [Savelyeva G.M., Sukhikh G.T., Serov V.N, Radzinsky V.E., Manukhin I.B., ed. National Guide. Gynecology. Moscow: GEOTAR-Media; 2022. 1008 p. (in Russian)].
  2. Bofill Rodriguez M., Lethaby A., Low C., Cameron I.T. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2019; 8(8): CD001016. https://dx.doi.org/10.1002/14651858.CD001016.pub3.
  3. Becker C.M., Bokor A., Heikinheimo O., Horne A., Jansen F., Kiesel L. et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum. Reprod. Open. 2022; 2022(2): hoac009. https://dx.doi.org/10.1093/hropen/hoac009.
  4. Barra F., Grandi G., Tantari M., Scala C., Facchinetti F., Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin. Biol. Ther. 2019; 19(4): 343-60. https://dx.doi.org/10.1080/14712598.2019.1581761.
  5. Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020; 76(1): 151-6. https:// dx.doi.org/10.1111/his.13977.
  6. Vercellini P., Bandini V., Buggio L., Barbara G., Berlanda N., Dridi D. et al. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? Hum. Reprod. Open. 2023; 2023(2): hoad008. https://dx.doi.org/10.1093/hropen/hoad008.
  7. Resta C., Moustogiannis A., Chatzinikita E., Ntalianis D.M., Ntalianis K.M., Philippou A. et al. Gonadotropin-releasing hormone (GnRH)/GnRH receptors and their role in the treatment of endometriosis. Cureus. 2023; 15(4): e38136. https://dx.doi.org/10.7759/cureus.38136.
  8. Surrey E.S. GnRH agonists in the treatment of symptomatic endometriosis: a review. F. S. Rep. 2022; 4(2 Suppl.): 40-5. https://dx.doi.org/10.1016/ j.xfre.2022.11.009.
  9. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Миома матки. 2020. 48 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Uterine fibroids. 2020. 48 p. (in Russian)].
  10. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2022. 42 c. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. 2022. 42 p. (in Russian)].
  11. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometrial hyperplasia. 2024. (in Russian)].
  12. Management of symptomatic uterine leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021 Jun 1;137(6):e100-e115. https:// dx.doi.org/10.1097/AOG.0000000000004401.
  13. Оразов М.Р., Хамошина М.Б., Муллина И.А., Артеменко Ю.С. Гиперплазия эндометрия – от патогенеза к эффективной терапии. Акушерство и гинекология: новости, мнения, обучение. 2021; 9(3): 21-8. [Orazov M.R., Khamoshina M.B., Mullina I.A., Artemenko Yu.S. Endometrial hyperplasia – from pathogenesis to effective therapy. Obstetrics and Gynecology: News, Opinions, Training. 2021; 9(3): 21-8. (in Russian)]. https:// dx.doi.org/10.33029/2303-9698-2021-9-3-21-28.
  14. Gong L., Zhang S., Han Y., Long Q., Zou S., Cao Y. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial. J. Clin. Pharmacol. 2015; 55(8): 848-53. https://dx.doi.org/10.1002/jcph.485.
  15. Адамян Л.В., Арсланян К.Н., Харченко Э.И., Логинова О.Н. Современные направления в медикаментозном лечении эндометриоза. Проблемы репродукции. 2019; 25(6): 58-66. [Adamyan L.V., Arslanyan K.N., Kharchenko E.I., Loginova O.N. Modern trends in the treatment of endometriosis. Russian Journal of Human Reproduction. 2019; 25(6): 58-66. (in Russian)]. https://dx.doi.org/10.17116/repro20192506158.
  16. Рухляда Н.Н., Бирюкова Е.И. Особенности фармакокинетики и биологические эффекты агонистов гонадотропин-рилизинг-гормона. Акушерство и гинекология. 2023; 2: 154-8. [Rukhlyada N.N., Biryukova E.I. The characteristics of pharmacokinetics and the biological effects of gonadotropin-releasing hormone agonists. Obstetrics and Gynecology. 2023; (2): 154-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.42.
  17. Рухляда Н.Н. Эффективность режима назначения Бусерелина-депо с пролонгированным межинъекционным интервалом: гормональный профиль и приемлемость лечения пациенток с эндометриозом. Акушерство и гинекология. 2023; 10: 153-8. [Rukhliada N.N. The effectiveness of the administration regimen of Buserelin-depo with a prolonged interval between injections: hormonal profile and acceptability of treatment for patients with endometriosis. Obstetrics and Gynecology. 2023; (10): 153-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.245.
  18. Хашукоева А.З., Агаева М.И., Савченко Т.Н., Агаева З.А., Бурденко М.В., Лобачева Ю.И. Применение Бусерелина-Депо в лечение сочетанной патологии органов репродуктивной системы. Акушерство и гинекология. 2024; 8: 170-4. [Khashukoeva A.Z., Agaeva M.I., Savchenko T.N., Agaeva Z.A., Burdenko M.V., Lobacheva Yu.I. The use of Buserelin-depo in the treatment ofcombined pathology of reproductive organs. Obstetrics and Gynecology. 2024; (8): 170-4 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.180.
  19. Пустотина О.А. Агонисты гонадотропин-рилизинг гормона и add-back терапия. Российский вестник акушера-гинеколога. 2023; 23(2): 63-9. [Pustotina O.A. Agonists of gonadotropin-releasing-hormone and add-back-therapy. Russian Bulletin of Obstetrician-Gynecologist. 2023; 23(2): 63-9. (in Russian)]. https://dx.doi.org/10.17116/rosakush20232302163.
  20. Хашукоева А.З., Агаева М.И., Агаева З.А., Савченко Т.Н., Лобачева Ю.И., Губожокова Л.Б., Лукьянова Е.А. Применение Бусерелина-Депо в лечении эндометриоза. Акушерство и гинекология. 2024; 11: 216-20. [Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Savchenko T.N., Lobacheva Yu.I., Gubzhokova L.B., Lukyanova E.A. The use of Buserelin-depo in the treatment of endometriosis. Obstetrics and Gynecology. 2024; (11): 216-20 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.287.
  21. Zhang K., Huang S., Xu H., Zhang J., Wang E., Li Y. et al. Effectiveness of gonadotrophin-releasing hormone agonist therapy to improve the outcomes of intrauterine insemination in patients suffering from stage I-II endometriosis. Ann. Med. 2022; 54(1): 1330-8. https://dx.doi.org/10.1080/ 07853890.2022.2071458.
  22. Yang Y., Zhu W., Chen S., Zhang G., Chen M., Zhuang Y. Laparoscopic surgery combined with GnRH agonist in endometriosis. J. Coll. Physicians Surg. Pak. 2019; 29(4): 313-6. https://dx.doi.org/10.29271/jcpsp.2019.04.313.
  23. Щукина Н.А., Буянова С.Н., Бабунашвили Е.Л., Тихомирова Е.В., Земскова Н.Ю., Глебов Т.А. Современные подходы к медикаментозному лечению пациенток с сочетанными пролиферативными заболеваниями матки. Российский вестник акушера-гинеколога. 2022; 22(6): 102-8. [Schukina N.A., Buyanova S.N., Babunashvili E.L., Tikhomirova E.V., Zemskova N.Yu., Glebov T.A. Current approaches to drug therapy in patients with concomitant proliferative uterine diseases. Russian Bulletin of Obstetrician-Gynecologist. 2022; 22(6): 102-8. (in Russian)]. https://doi.org/10.17116/rosakush202222061102.
  24. Zhang Y., Sun L., Guo Y., Cheng J., Wang Y., Fan S. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet. Gynecol. Surv. 2014; 69(2): 100-8. https://dx.doi.org/10.1097/OGX.0000000000000036.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media